Amgen just announced that it will invest $200 M in a new flexible manufacturing facility for biopharmaceuticals in Singapore. It joins other giants of the industry including Pfizer, Lonza, Roche and Baxter with Singapore operations. This past November, Novartis also announced plans to build a $500M cell culture based manufacturing center in Singapore.
The island nation is hot. Over 50 commercial scale manufacturing plants now operate in Singapore. The number of employees in these operations have grown from 6000 to 15,000 in the past 10 years. Manufacturing output has also grown from $6B to over $27B in that time span.
Singapore is attractive due to its strong talent base, proven track record in manufacturing, reliable infrastructure, trusted supply chain, business friendly policies including generous financial incentives for multinational groups. It is reminiscient to past pharma manufacturing hubs like Puerto Rico and Ireland. It is perceived as a gatewway to Asia and no bdoubt it's time has come to experience rapid growth and prosperity.
Posted by Bruce Lehr Jan 23rd 2013.